ImmunoGen to Receive $34 Million 1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Payments as well as Double-Digit Royalties Collaboration Further Supports Strategy to Bring ELAHERE to Eligible Patients with Folate Receptor Alpha
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates Cash Runway Extended Through Readout of Mirvetuximab Soravtansine Pivotal Trial in Ovarian Cancer Conference Call to be Held at 8 a.m. ET Today WALTHAM, Mass.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call atĀ 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 30, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 29, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 10, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 15, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.